Fibrosis: Oncodesign and TiumBio sign collaboration agreement for R&D of drug candidates
Under this agreement, Oncodesign will be responsible for identification, chemical synthesis and optimization of Nanocyclix® drug candidates and their early-stage analysis, while TiumBio will be responsible for the advanced evaluation of fibrotic efficacy of the drug candidates. This initial phase of the collaboration will be funded by TiumBio.
Our organization by Business Unit boosts the quality of our active compounds
To boost the quality of each compound, our company has been organized into Business Units since January 2020. This organization also aims to make the Group’s activities clearer for employees, customers, partners and investors. Each BU has its own objectives and resources. They will naturally lead to subsidiaries in the coming years depending on their level of maturity.
"Oncodesign has been listed on Euronext Growth Market since April 2014 (ALONC, Paris). Our biggest goal since our creation has been to discover effective therapies to fight cancer and other diseases for which no treatment is currently available. We have built a unique platform ofprecision medicine dedicated to resistant or refractory diseases (...)"